Spy Biotech, Ltd.
SpyBiotech is a biotechnology company focused on developing vaccines against infectious diseases, cancer, and chronic diseases using its proprietary protein superglue technology, SpyTag/SpyCatcher. The company aims to address major human health challenges worldwide with safe, effective, and scalable vaccine solutions.
Industries
Nr. of Employees
small (1-50)
Spy Biotech, Ltd.
Oxford, Oxfordshire, United Kingdom, Europe
Products
HCMV VLP vaccine candidate (virus-like particle format)
A virus-like-particle vaccine candidate targeting human cytomegalovirus developed using modular antigen display on hepatitis B-derived VLP scaffolds; advanced into early-phase clinical studies.
Preclinical coronavirus RBD nanoparticle vaccine candidate
A receptor-binding-domain (RBD) nanoparticle vaccine candidate constructed by covalent attachment of RBD antigens to particulate scaffolds; demonstrated high neutralising antibody titres in preclinical studies.
HCMV VLP vaccine candidate (virus-like particle format)
A virus-like-particle vaccine candidate targeting human cytomegalovirus developed using modular antigen display on hepatitis B-derived VLP scaffolds; advanced into early-phase clinical studies.
Preclinical coronavirus RBD nanoparticle vaccine candidate
A receptor-binding-domain (RBD) nanoparticle vaccine candidate constructed by covalent attachment of RBD antigens to particulate scaffolds; demonstrated high neutralising antibody titres in preclinical studies.
Services
Platform licensing and collaborative R&D
Provision of a modular antigen-display platform to partners via licensing and sponsored research agreements to support vaccine design and development across multiple delivery systems.
Collaborative vaccine development and clinical support
Collaborative development of vaccine candidates including preclinical testing, formulation, regulatory filings and early-phase clinical trial initiation support.
Platform licensing and collaborative R&D
Provision of a modular antigen-display platform to partners via licensing and sponsored research agreements to support vaccine design and development across multiple delivery systems.
Collaborative vaccine development and clinical support
Collaborative development of vaccine candidates including preclinical testing, formulation, regulatory filings and early-phase clinical trial initiation support.
Expertise Areas
- Vaccine platform development (antigen display on particles)
- Virus-like particle (VLP) and nanoparticle vaccine design
- Preclinical immunology and animal-model testing
- Early-phase clinical trial execution
Key Technologies
- Covalent protein linkage for antigen display
- Virus-like particles (VLPs)
- Computationally designed protein nanoparticles
- Ferritin and other nanoparticle scaffolds